One father's heartbreak inspired a $250M quest for a cure

How one father's loss turned into gain for cystic fibrosis patients and Vertex Pharmaceuticals ($VRTX): After the death of his son, Boston businessman Joe O'Donnell spent years raising $250 million for the Cystic Fibrosis Foundation, which backed Vertex's development of the groundbreaking treatment Kalydeco. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.